Drug Profile


Alternative Names: Alginate oligosaccharide (G-block) fragment; Oligo-COPD-10/20(1); OligoG CF-5/20; OligoG-COPD-5/20; Oligosaccharide nanotherapeutic - AlgiPharma

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Norwegian university of science and technology
  • Developer AlgiPharma
  • Class Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Bronchodilators; Oligosaccharides
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis
  • Phase I Chronic obstructive pulmonary disease
  • Preclinical Bacterial infections; Mycoses

Most Recent Events

  • 10 May 2016 AlgiPharma completes a phase IIb trial for Cystic fibrosis in Germany (NCT02453789)
  • 31 Mar 2016 Phase-II clinical trials in Cystic fibrosis in Norway (Inhalation, powder) (NCT02157922)
  • 22 Mar 2016 AlgiPharma completes enrolment in a phase IIb trial for Cystic fibrosis in Germany (NCT02453789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top